Harmony Biosciences (HRMY) announced the commencement of an underwritten public offering of up to 8M shares of the company’s common stock by Marshman Fund Trust II and Valor IV Pharma Holdings. The company is not offering any shares of common stock in the proposed offering and will not receive any proceeds from the proposed offering. J.P. Morgan is acting as the sole book-running manager for the offering.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences reports Q3 adjusted EPS $1.03, consensus 66c
- Harmony Biosciences still sees 2024 product revenue $700M-$720M
- HRMY Upcoming Earnings Report: What to Expect?
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- Harmony Biosciences resumed with an Outperform at Raymond James